Enhancement Characteristics of Ultrasmall Superparamagnetic Iron Oxide Particle Within the Prostate Gland in Patients With Primary Prostate Cancer

Li, Chao-Shiang; Harisinghani, Mukesh G.; Wang, Lin; Braschi, Martha; Hahn, Peter F.; Müeller, Peter R.

doi:10.1097/rct.0b013e318136e194

Cited by 10 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study also confirmed the efficiency of imaging techniques especially MRI for PCa diagnosis [85]. Previously, Li, Chao-Shiang et al used USPION as a contrast agent in MRI to detect PCa in the primary stage [86]. In this study, 60 patients were included where central zones (CZ) and peripheral zones (PZ) of prostate were assayed by T2-and T2*-weighted MRI in association with USPION-enhanced MRI.…”

Section: Detection Of Metastasessupporting

confidence: 75%

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignancy in men and the leading cause of death for men all over the world. Early diagnosis is the key to start treatment at an early stage of PCa and to reduce the death toll. Generally, PCa expresses characteristic morphologic features and serum biomarkers; however, early diagnosis is challenging due to its heterogeneity and long-term indolent phase in the early stage. Following positive diagnosis, PCa patients receive conventional treatments including surgery, radiation therapy, androgen deprivation therapy, focal therapy, and chemotherapy to enhance survival time and alleviate PCa-related complications. However, these treatment strategies have both short and long-term side effects, notably impotence, urinary incontinence, erectile dysfunctions, and recurrence of cancer. These limitations warrant the quest for novel PCa theranostic agents with robust diagnostic and therapeutic potentials to lessen the burden of PCa-related suffering. Iron oxide nanoparticles (IONPs) have recently drawn attention for their symmetrical usage in the diagnosis and treatment of several cancer types. Here, we performed a systematic search in four popular online databases (PubMed, Google Scholar, Scopus, and Web of Science) for the articles regarding PCa and IONPs. Published literature confirmed that the surface modification of IONPs with biopolymers and diagnostic biomarkers improved the early diagnosis of PCa, even in the metastatic stage with reliable accuracy and sensitivity. Furthermore, fine-tuning of IONPs with biopolymers, nucleic acids, anticancer drugs, and bioactive compounds can improve the therapeutic efficacy of these anticancer agents against PCa. This review covers the symmetrical use of IONPs in the diagnosis and treatment of PCa, investigates their biocompatibility, and examines their potential as PCa theranostic agents.

show abstract

Section: Detection Of Metastasessupporting

confidence: 75%

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…28 However, in the glandular peripheral zone and anterior gland, DCE-MRI can be quite helpful in identifying lesions that are not suspected on T2W images. 29 Li et al 30 demonstrated the association between prostate enhancement after USPIO particle administration and tumor grade in 60 patients with primary prostate cancer; the degree of enhancement (negative contrast in the case of USPIOs) correlated positively with tumor grade. DCE-MRI alone has reported sensitivity and specificity ranges of 46–96% and 74–96%, respectively, for detection of tumor lesions, but, as always, these ranges are highly dependent on patient selection, technique and diagnostic criteria.…”

Section: Current Imaging Modalitiesmentioning

confidence: 99%

Imaging techniques for prostate cancer: implications for focal therapy

2009

View full text Add to dashboard Cite

The multifocal nature of prostate cancer has necessitated whole-gland therapy in the past; however, since the widespread use of PSA screening, patients frequently present with less-advanced disease. Many men with localized disease wish to avoid the adverse effects of whole-gland therapy; therefore, focal therapy for prostate cancer is being considered as a treatment option. For focal treatment to be viable, accurate imaging is required for diagnosis, staging, and monitoring of treatment. Developments in MRI and PET have brought more attention to prostate imaging and the possibility of improving the accuracy of focal therapy. In this Review, we discuss the advantages and disadvantages of conventional methods for imaging the prostate, new developments for targeted imaging, and the possible role of image-guided biopsy and therapy for localized prostate cancer.

show abstract

“…Ultrasmall superparamagnetic iron oxide-enhanced MRI can also be used in the diagnosis of primary prostate cancer (57). In patients with prostate cancer, ultrasmall superparamagnetic iron oxide-enhanced MRI may demonstrate a characteristic decrease in the signal-to-noise ratio of the prostate gland.…”

Section: Goldmentioning

confidence: 99%

Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles

2016

Self Cite

View full text Add to dashboard Cite

Over the last 2 decades, the use of nanoparticle imaging has been investigated extensively for both diagnosis and therapy of prostate cancer. This review discusses the various classes of nanoparticles currently in clinical use or at the advanced preclinical stage. In particular, we focus on the unique properties of nanoparticles, as a group, that make them suitable for imaging and therapy. The characteristics of each nanoparticle are detailed. Iron oxide nanoparticles, extensively used for MRI of prostate cancer, are discussed in depth.

show abstract

Enhancement Characteristics of Ultrasmall Superparamagnetic Iron Oxide Particle Within the Prostate Gland in Patients With Primary Prostate Cancer

Abstract: Enhancement of the prostate gland after USPIO administration may be associated with primary prostate cancer.

Cited by 10 publications

References 31 publications

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

Imaging techniques for prostate cancer: implications for focal therapy

Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles

Contact Info

Product

Resources

About